Zogenix To Present New Case Study Highlighting Successful Repositioning Of Injectable Sumatriptan For Migraine With A Novel Needle-Free Delivery Technology

For full prescribing information, please click here: http://www.zogenix.com/downloads/SV0468.0611_SDP_PI.pdf

For more information about SUMAVEL DosePro, please visit www.SUMAVELDosePro.com.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL ^® DosePro ^® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, Zohydro™ ER (hydrocodone bitartrate) is an oral, extended-release formulation of various strengths of hydrocodone, without acetaminophen, intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, Relday™, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com . SUMAVEL®, DosePro®, Relday ^TM and Zohydro ^TM are trademarks of Zogenix, Inc.

CONTACT: ZOGENIX INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | [e-mail]
         
         ZOGENIX MEDIA:
         Victoria Aguiar | The Ruth Group
         646.536.7013 | [e-mail]

« First ‹ Previous 1 2 3 4